Skip to content

Basic and clinical innovative research on vesicourethral dysfunction and its multidimensional regulation - Building a predictive model based on machine learning algorithm to evaluate the efficacy of intravesical electrical stimulation for neurogenic bladder

Basic and clinical innovative research on vesicourethral dysfunction and its multidimensional regulation - Building a predictive model based on machine learning algorithm to evaluate the efficacy of intravesical electrical stimulation for neurogenic bladder

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400088594
Enrollment
Unknown
Registered
2024-08-22
Start date
2023-12-04
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurogenic bladder

Interventions

model training set group:NA
model test set group:NA

Sponsors

China Rehabilitation Research Center,Beijing Boai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) The neurogenic bladder aged 18-75 (including boundary values), regardless of gender; (2) Patients who have been diagnosed with UAB and have a course of disease greater than 3 months; (3) Patients who have previously undergone intermittent catheterization to empty the bladder, or have indications for intermittent catheterization (residual urine volume accounting for over 40% of the functional bladder capacity); (4) Those who voluntarily sign a written informed consent form; (5) Those who can communicate well with researchers and are willing to follow the entire experimental requirements.

Exclusion criteria

Exclusion criteria: (1) Patients with low bladder compliance (less than 20ml/cmH2O) during urodynamic examination; (2) Patients with combined mechanical obstruction of the outflow tract; (3) Patients with complete spinal cord injury; (4) Patients with concurrent symptomatic urinary tract infections; (5) Patients with Hydronephrosis or bladder ureter reflux; (6) Patients with concomitant renal insufficiency (blood creatinine greater than 1.5 times the upper limit of normal); (7) Patients with malignant tumors of the bladder and prostate; (8) Patients with implanted pacemakers or defibrillators; (9) Senile dementia, Cerebral atrophy, Cerebrovascular disease in acute stage, cognitive impairment (10) Epilepsy, Mental disorder can not cooperate with doctors; (11) Patients with positive infectious diseases screening (hepatitis B surface antigen, hepatitis C antibody, syphilis antibody and HIV antibody) before surgery; (12) Pregnant women or patients preparing to conceive; (13) Those who have participated in other clinical trials three months before the trial; (14) Other situations where the researcher deems it inappropriate to participate in the study.

Design outcomes

Primary

MeasureTime frame
Change in urination frequency from baseline;American Urological Association Symptom Index,AUA-SI;Residual urine volume change;

Secondary

MeasureTime frame
Frequency of urgent urination;Nocturia frequency;Frequency of urinary incontinence;Volume of urine per discharge;Patient Perception of Bladder Condition- Scale, PPBC-S;quality of life;neurogenic bowel dysfunction;Maximum urine flow rate;Bladder emptying efficiency;Intermittent catheterization times;Proportion of patients completely disengaged from intermittent catheterization;The incidence of adverse events;

Countries

China

Contacts

Public ContactLiao Limin

China Rehabilitation Research Center,Beijing Boai Hospital

lmliao@263.net+86 10 8756 9043

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026